Efficacy of Parecoxib on Patients With CRPS
Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Christoph Maier, Ruhr University of Bochum
First received: January 31, 2012
Last updated: April 24, 2012
Last verified: April 2012
The complex regional pain syndrom is a weighty disease that often results in a lifelong disability. Mostly this disease appears unilateral after comparatively mundane fractures or operations. In early stages CRPS shows inflammatory processes. These inflammatory components can be seen as edema and vasodilatation. These inflammatory processes lead us to the hypothesis that selective COX-2-inhibitors might help patients with CRPS.
What is Expanded Access?
||Efficiacy of the Selctive COX-2-inhibitor Parecoxibe on the Pathological Low Pressure Pain Threshold (PPT) of Patients With Complex Regional Pain Syndrome (CRPS)
90mg Parecoxib i.v. two times a day, two days in a row
Other Name: Dynastat
NaCl i.v. two times a day, two days in an row
Other Name: sodium chlorid
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
- Patients with saved diagnosis of CRPS of the upper extremity based on the current used criteria for diagnosis plus a positiv 3-phase-sceletal-scintilgraphy, if they show pathological PPT-values in QST on the ipsilateral site (Z-values > 2 in age- and gender-based Z-transformation of the raw values)• age ≥ 18 years• Existence of an age-based normal creatinin-clearance (calculated with a defined formula)
Important cardiovascular illness for the purpose of heart failure (NYHA II - IV), coronary heart disease (CHD), peripheral artery occlusive disease (PAOD) or unstable hypertension (values constantly over 140/90 mm Hg)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Christoph Maier, Prof. Dr., Ruhr University of Bochum
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 31, 2012
||April 24, 2012
||Germany: Federal Institute for Drugs and Medical Devices
Keywords provided by Ruhr University of Bochum:
complex regional pain syndrome
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 16, 2014
Complex Regional Pain Syndromes
Autonomic Nervous System Diseases
Nervous System Diseases
Peripheral Nervous System Diseases
Cyclooxygenase 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents